Health Discovery Corporation and Doctors Optimal Formula Launching Retinalyze Analytics for Detection of Macular Degeneration
Retinalyze Analytics will initially be used for age-related macular degeneration ("AMD"), a progressive eye disease affecting more than 15 million Americans, with over 200,000 new cases diagnosed each year. AMD is the leading cause of blindness in adults 55 years and older which can result in severe visual loss because it affects the macula portion of the eye, where the sharpest central vision occurs.
Coinciding with the upcoming launch, the website www.retinalyze.com will be unveiled. This website will provide an extensive health care library relating to eye diseases. Additionally, we will offer a Macular Degeneration Risk Assessment tool that will help evaluate the patients risk factors for developing macular degeneration. It will also provide very useful information on how best to prevent, minimize and/or treat their eye disease. Patients will be able to learn more about their eye disease, as well as, Retinalyze Analytics can also search for Retinalyze Providers in their area.
"With Doctors Optimal Formulas current extensive physician network of over 7,000 eye doctors, we expect thousands of Ophthalmologists and Optometrists to begin utilizing Retinalyze Analytics within the first few months after this initial launch," states Howard Loff, MD, a renowned Oculo-Plastic Surgeon and CEO of Doctors Optimal Formula.
"For the first time were able to objectively quantify eye disease and very precisely monitor for even the most subtle of changes that even the Human Eye cant see," exclaims Dr. Sunil Malkani, a Vitreo-Retinal specialist. "Moreover, were incredibly excited about the applications this affords not only with Macular Degeneration but also with other retinal diseases including cancerous eye lesions. The earlier we can diagnose these diseases, the better we can treat and ultimately save vision or even lives."
"We are very excited that with thousands of attendees scheduled for this optometric convention, this will provide an ideal platform to launch our ground-breaking vision-saving technology," exclaims Howard Loff, MD. "With a sensitivity of greater than 95% accuracy in assisting with the diagnosis of AMD, Retinalyze has the ability to create a new standard of care for eye diseases and in the very near future could be used by the vast majority of eye doctors. The initial pricing structure will include a continuing monthly participation fee of $25 per doctor and a $15 per patient fee for each Retinalyze scan. I not only see this as being a primary tool used by the more than 60,000 eye doctors here in the US but also by those around the world."
Dr. Stephen Barnhill, Chairman and CEO of Health Discovery Corp, stated, "We are very proud of the work of Health Discovery Corporations SVM image analysis expert Dr. Hong Zhang and his use of HDCs patented Support Vector Machine Technology in the development of Retinalyze Analytics." Dr. Barnhill continued, "As a 50% joint venture owner in Retinalyze, LLC, HDC could recognize significant revenue in the very near term as a result of the potential success of Retinalyze Analytics in the Ophthalmic arena."
About Doctors Optimal Formula LLC
Having been founded by medical doctors, Doctors Optimal Formula prides itself on providing the best, scientifically formulated nutritional supplements and anti-aging skin care available today! Focusing on maintaining and improving the health and well-being of our customers, Doctors Optimal Formula has become vertically integrated to encompass all aspects of healthcare, such as Vision Care Plans, Prescription Pharmacy Plans and a physician provider network of over 10,000 physicians. For more information, visit www.DoctorsOptimalFormula.com.
About Health Discovery Corporation
Health Discovery Corporation is a molecular diagnostics company that uses advanced mathematical techniques to analyze large amounts of data to uncover patterns that might otherwise be undetectable. It operates primarily in the emerging field of personalized medicine where such tools are critical to scientific discovery. Its primary business consists of licensing its intellectual property and developing its own product line of biomarker-based diagnostic tests that include human genes and genetic variations, as well as gene, protein, and metabolic expression differences and image analysis in digital pathology and radiology. For more information, see www.healthdiscoverycorp.com.